

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

A speed-fidelity trade-off determines the mutation rate and virulence of an RNA virus

Running Title: Speed-fidelity trade-off

Biological Sciences; Evolution, Microbiology

William Fitzsimmons¹, Robert J. Woods¹, John T. McCrone², Andrew Woodman³, Jamie J. Arnold³, Madhumita Yennawar³, Richard Evans⁴, Craig E. Cameron³, and Adam S. Lauring^{1,2*}

¹ Division of Infectious Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109

² Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI 48109

³ Department of Biochemistry and Molecular Biology, Pennsylvania State University, University Park, Pennsylvania 16802

⁴ Department of Epidemiology, University of Michigan, Ann Arbor, MI 48109

* Corresponding author

Adam S. Lauring

1150 W. Medical Center Dr.

MSRB1 Room 5510B

Ann Arbor, MI 48109-5680

alauring@med.umich.edu

27 **Abstract**

28 Mutation rates can evolve through genetic drift, indirect selection due to genetic hitchhiking, or
29 direct selection on the physicochemical cost of high fidelity. However, for many systems, it has
30 been difficult to disentangle the relative impact of these forces empirically. In RNA viruses, an
31 observed correlation between mutation rate and virulence has led many to argue that their
32 extremely high mutation rates are advantageous, because they may allow for increased
33 adaptability. This argument has profound implications, as it suggests that pathogenesis in many
34 viral infections depends on rare or *de novo* mutations. Here we present data for an alternative
35 model whereby RNA viruses evolve high mutation rates as a byproduct of selection for
36 increased replicative speed. We find that a poliovirus antimutator, 3D^{G64S}, has a significant
37 replication defect and that wild type and 3D^{G64S} populations have similar adaptability in two
38 distinct cellular environments. Experimental evolution of 3D^{G64S} under r-selection led to
39 reversion and compensation of the fidelity phenotype. Mice infected with 3D^{G64S} exhibited
40 delayed morbidity at doses well above the LD₅₀, consistent with attenuation by slower growth as
41 opposed to reduced mutational supply. Furthermore, compensation of the 3D^{G64S} growth defect
42 restored virulence, while compensation of the fidelity phenotype did not. Our data are consistent
43 with the kinetic proofreading model for biosynthetic reactions and suggest that speed is more
44 important than accuracy. In contrast to what has been suggested for many RNA viruses, we find
45 that within host spread is associated with viral replicative speed and not standing genetic
46 diversity.

47

48 Key words – mutation rate, evolution, RNA virus, pathogenesis

49

50 **Author Summary**

51 Mutation rate evolution has long been a fundamental problem in evolutionary biology. The
52 polymerases of RNA viruses generally lack proofreading activity and exhibit extremely high

53 mutation rates. Since most mutations are deleterious and mutation rates are tuned by natural
54 selection, we asked why hasn't the virus evolved to have a lower mutation rate? We used
55 experimental evolution and a murine infection model to show that RNA virus mutation rates may
56 actually be too high and are not necessarily adaptive. Rather, our data indicate that viral
57 mutation rates are driven higher as a result of selection for viruses with faster replication kinetics.
58 We suggest that viruses have high mutation rates, not because they facilitate adaptation, but
59 because it is hard to be both fast and accurate.

60

61 **Introduction**

62 Mutation is the ultimate source of genetic variation, and mutation rates can have a significant
63 impact on evolutionary rate [1-3]. The intraspecific variability in mutation rate in many viruses
64 and bacteria indicates that mutation rates have been optimized by natural selection [4-13].
65 Given that most mutations are deleterious, the burden of excess mutational load will select
66 against strains with abnormally high mutation rates [14-17]. This principle led to Sturtevant to
67 ask, "Why does the mutation rate not evolve to zero?" [18,19].

68

69 A large body of theoretical and experimental work suggests that the selective pressure for
70 higher mutation rates is due to either the physicochemical cost of maintaining a lower one or a
71 selective advantage from an increased supply of beneficial mutations [20-23]. Many have
72 argued for the adaptive benefit of high mutation rates in pathogenic microbes, which often exist
73 in dynamic environments and are subject to host immune pressure [7,24,25]. However, direct
74 selection of a variant with a higher mutation rate will only occur if it has been advantageous in
75 the past, and in many cases, it has been difficult to separate the causes of a higher mutation
76 rate from its consequences [19,26].

77

78 RNA viruses are ideal systems for studying the selective forces that act on mutation rates. While
79 interspecific mutation rates range from 10^{-4} to 10^{-6} errors per nucleotide copied [4], studies of
80 antimutators and hypermutators suggests that fidelity can only vary by several fold within a
81 species [27]. The severe burden of mutational load exerts a strong downward pressure on
82 mutation rates and hypermutator strains are attenuated *in vivo* [9,28-31]. Given the short
83 generation times and remarkable fecundity of many RNA viruses, a small kinetic cost to higher
84 fidelity should result in strong selection against antimutators [32,33]. However, the observed
85 attenuation of antimutator RNA viruses *in vivo* has led many to argue for the adaptive benefit of
86 high mutation rates, as genetic diversity provides a rich substrate for a virus' evolution in the
87 face of varying intrahost environments [7,10,34-38]. This concept is central to viral quasispecies
88 theory, which generally proposes a link between genetic diversity and viral fitness [24,25].

89

90 Here, we define the selective forces that shape viral mutation rates by studying an antimutator
91 variant. The 3D^{G64S} mutant of poliovirus was selected after serial passage in ribavirin, an RNA
92 virus mutagen. The RNA dependent RNA polymerase (RdRp, 3D) of this variant contains a
93 single glycine to serine substitution [5-7]. The basal mutation rate of 3D^{G64S} is reported to be
94 ~20-30% that of wild type virus (WT). While the 3D^{G64S} mutant is attenuated in poliovirus
95 receptor transgenic mice, the relative importance of replicative speed and fidelity to this
96 phenotype is not clear [7,36]. Biochemical assays of 3D^{G64S} suggest a physicochemical cost of
97 high fidelity, but as in other systems, its contribution to overall fitness remains unquantified
98 [6,19,39].

99

100 **Results**

101 We measured the relative fitness of 3D^{G64S} by direct competition over serial passage by RT-
102 qPCR (Fig. 1A). Here, the fitness of 3D^{G64S} is 0.78 ± 0.01 (n=3 replicates) relative to WT. This is
103 a moderate fitness defect, falling in the 64th percentile in a dataset of 8970 fitness values

104 obtained for point mutants of poliovirus under similar conditions [16] (e.g. HeLa cells, moi 0.1, 8
105 hour infection cycle, and 6 passages; Fig. 1B). We also measured the relative growth properties
106 of WT and 3D^{G64S} using a plaque size assay, which measures the growth, burst size, and
107 spread of individual viruses in the absence of competition [40-42]. The distribution of clonal
108 plaque sizes was significantly different ($p < 0.005$, unpaired t-test with Welch correction, $n = 272$
109 WT and $n = 220$ 3D^{G64S} plaques), and consistent with a moderate fitness defect in 3D^{G64S} (Fig.
110 1C). In contrast to prior work, we were able to detect a significant replication defect for 3D^{G64S} by
111 one step growth curve, but only with rigorous synchronization, more frequent time points, and
112 larger numbers of replicates (Fig. 1D). This replication defect was not specific to HeLa, as we
113 observed a similar lag for 3D^{G64S} in a 3T3 cell line that we derived from mouse embryonic
114 fibroblasts from poliovirus receptor transgenic mice (PVR-3T3, Fig. 1E). These data
115 demonstrate that the fitness defect of 3D^{G64S} is largely attributable to its slower replicative
116 kinetics and is consistent with biochemical assays on purified RdRp [6,39].

117
118 The reduced mutation rate and replicative fitness of 3D^{G64S} suggest a trade-off between speed
119 and fidelity in RNA virus replication. Here, the fitness gain from increased replicative speed is
120 offset by a reduction in fitness due to increased mutational load. We derived a quantitative
121 model of this trade-off (see SI Model 1) by measuring the replicative fitness (Fig. 1F) and
122 mutation rate (Fig. 1G, Table S1) of WT and 3D^{G64S} under exposure to an exogenous mutagen,
123 ribavirin [43]. Wild type and 3D^{G64S} had equal fitness at approximately 150 μ M ribavirin. Based
124 on these data, our model indicates that WT incurs a fitness cost of 0.137 from mutational load
125 alone. Therefore, any fitness benefit of the high baseline mutation rates in WT would
126 presumably need to offset this cost. In 3D^{G64S}, the cost of mutational load is reduced to 0.037.

127
128 If viral RdRp are constrained by a speed-fidelity trade-off, selection for increased replicative
129 speed (r-selection) will increase mutation rate. We subjected the 3D^{G64S-1nt} point mutant

130 (A6176G) to r-selection over serial passage by infecting cells at low multiplicity and harvesting
131 progeny at 4.5 hours (mid-exponential phase of replication). The 3D^{G64S} point mutant reverted to
132 WT within 15 passages in 5 independent lineages (Fig. 2A). We only observed partial reversion
133 at passage 15 in a subset of 24-hour control lineages, in which virus populations underwent
134 twice as many cellular infection cycles per passage and experienced reduced r-selection. We
135 next asked whether r-selection would lead to genetic compensation of the fidelity phenotype in
136 3D^{G64S-3nt}, which has all three positions in the codon mutated to minimize reversion. After 50
137 passages of r-selection, we identified fixed and polymorphic single nucleotide variants (SNV) by
138 next generation sequencing of all r-selected and control (24 hour passage) populations of
139 3D^{G64S} and WT (Fig. 2B).

140
141 Unbiased hierarchical clustering of SNV by type and frequency indicates that the viruses
142 explored distinct mutational pathways in adapting to either r-selective or control passaging
143 regimes. Within the r-selected group, WT and 3D^{G64S} lineages clustered together and we noted
144 a larger number of SNV within the coding region for the RdRp across the five 3D^{G64S} populations.
145 Not surprisingly, we found that a number of distinct SNV increased viral fitness when introduced
146 into the ancestral WT backbone. For example, the WT-VP4^{S22G} had a fitness of 1.53, and its
147 presence in all r-selected and control lineages suggests that it mediates adaptation to HeLa
148 cells. In contrast, a mutation in the viral helicase found only in r-selected populations, 2C^{V127L}
149 (fitness 1.52-1.67 in WT and 1.11 ± 0.02 in 3D^{G64S}), would be more likely to have a general
150 effect on replicative speed.

151
152 To identify compensatory mutations, we focused our subsequent analysis on nonsynonymous
153 mutations in the RdRp that were found predominantly in r-selected populations, shared among
154 multiple lineages, and more frequent in 3D^{G64S} than in WT. Two mutations – U6261C/3D^{I92T} and
155 A6813G/3D^{K276R} – met these criteria, and their frequencies at passages 30 and 50 suggest that

156 the I92T mutation may have arisen first. The 3D^{I92T} mutation, which was found in both r-selected
157 WT (3/5) and 3D^{G64S} (5/5) lineages, did not change either fitness or mutation rate appreciably in
158 the 3D^{G64S} background (Fig. 2C and 2D). The r-selected K276R substitution, which was found in
159 3D^{G64S} lineages (4/5) and not in WT populations, decreased overall fitness in both WT ($0.92 \pm$
160 0.03 , $p=0.0031$ vs. WT, t-test) and 3D^{G64S} (0.55 ± 0.03 , $p=0.005$ vs. 3D^{G64S}, t-test). It had no
161 detectable effect on mutation rate in either background. The G64S/I92T/K276R triple mutant
162 had a significant increase in fitness (0.7637 , $p=0.0012$ vs. 3D^{G64S}, t-test) and mutation rate (8.71
163 $\times 10^{-6}$ s/n/r, $p=0.0120$ vs. 3D^{G64S}, t-test) compared to 3D^{G64S} and each double mutant. Therefore,
164 direct selection for replicative speed caused an increase in the poliovirus mutation rate with sign
165 epistasis among the G64S, I92T, and K276R in the RdRp.

166

167 To gain mechanistic insight into the interactions among these three mutations, we analyzed the
168 kinetics of single-base incorporation and misincorporation by purified RdRp. The 3D^{G64S ; I92T}
169 RdRp exhibits an assembly defect relative to 3D^{I92T} when incubated with purified primer-
170 template and ATP (Fig. 2E and [6]). The K276R mutation partially compensates for this
171 assembly defect in the 3D^{G64S ; I92T} background, resulting in a 1.5-2 fold increase in incorporation
172 of the correct nucleotide (A opposite U). This interaction is dependent on G64S, as K276R
173 reduced RdRp activity in the 3D^{I92T} background. While some poliovirus mutators exhibit altered
174 kinetics of base misincorporation for G opposite U [30], the kinetics of 3D^{G64S ; I92T ; K276R} were
175 similar to those of 3D^{G64S ; I92T} (Fig. S1).

176

177 The adaptability of WT and high fidelity viruses have generally been compared using assays
178 that measure the acquisition of drug resistance, the reversion of an attenuating point mutation,
179 or escape from microRNA in a limited number of replication cycles [5-7,34,36]. In these
180 experiments, mutations come at little cost, and the assays essentially quantify the beneficial
181 mutation rate. To capture better the impact of both deleterious and beneficial mutations on

182 adaptability, we measured the fitness gain of WT and 3D^{G64S} over twenty passages in HeLa.

183 While our WT strain is “culture-adapted,” we found that it was far from a fitness peak; both WT

184 and 3D^{G64S} increased their fitness ten-fold in approximately 40 cellular infection cycles (20

185 passages, Fig. 3A, Fig. S2). The difference in the rate of fitness gain between WT and 3D^{G64S}

186 lineages was small but statistically significant (0.025 per passage, WT > 3D^{G64S}; mixed linear

187 effects model, $p=0.0129$).

188

189 We examined adaptation to a completely distinct environment by repeating the experiment on

190 our PVR-3T3 cell line [44,45]. In this alternative species and cell type, we actually observed

191 greater fitness gain in the high fidelity 3D^{G64S} variant relative to WT (0.121 per passage; mixed

192 linear effects model, $p=0.0013$). The larger fitness gain in 3T3 cells may reflect a larger supply

193 of beneficial, compensatory mutations given the lower baseline fitness of 3D^{G64S} in these cells.

194 These data suggest that, despite its two-fold reduction in mutation rate, 3D^{G64S} is not mutation

195 limited, and that any adaptive benefit of a higher mutation rate is countered by the fitness cost of

196 increased mutational load (see Fig. 1F and 1G and associated model above).

197

198 We next compared the phenotype of WT and 3D^{G64S} viruses *in vivo*, where the ability to

199 generate genetic diversity may allow a virus to escape host immune restriction and to replicate

200 better in a range of environments. Importantly, the available data have suggested that the

201 attenuation of 3D^{G64S} and other high fidelity variants in experimental models is attributable to

202 differences in the genetic diversity of the infecting population [7]. We therefore used next

203 generation sequencing to compare the genetic diversity of 5 replicate stocks each of WT and

204 3D^{G64S}. Using an internally benchmarked analysis pipeline that dramatically reduces false

205 positive variant calls (see [46] and Methods), we identified no variants at greater than 0.1%

206 frequency. Therefore, we can exclude any significant differences in standing genetic diversity

207 between our WT and 3D^{G64S} populations. Even at extremely high multiplicities of infection,

208 variants present at <0.1% are unlikely to complement each other or to cooperate reproducibly in
209 a cellular context or in vivo [47].

210

211 The absence of mutational diversity in our replicate WT and 3D^{G64S} stocks is important, as
212 poliovirus populations are subject to stringent bottleneck events, which further restrict intrahost
213 diversity [48-50]. Work with barcoded RNA viruses suggests that the serial bottlenecks between
214 the infecting population and the terminal population colonizing the central nervous system
215 (CNS) are quite stringent [51,52], and we used published data to quantify the aggregate
216 bottleneck size encountered by poliovirus in transgenic mice [45,48,49]. Maximum likelihood
217 optimization of a simple probabilistic model estimated an aggregate bottleneck size of 2.67
218 between the inoculum and the CNS (Fig. 4A, SI Model 2). Therefore, the population that causes
219 eventual disease in these mice is derived from no more than 2-3 viruses in the infecting
220 population. In the setting of tight bottlenecks, many mutations will increase in frequency due to
221 genetic drift as opposed to positive selection.

222

223 We infected groups of PVR mice intramuscularly with both WT and 3D^{G64S} populations. Both
224 viruses were able to access the CNS efficiently through this route over a range of doses (Fig.
225 4B, Table S2), but there was a clear delay in the 3D^{G64S} group ($p=0.0239$, $p<0.001$, $p<0.001$ for
226 10^5 , 10^6 , 10^7 pfu inocula, respectively). This lag persisted even when we increased the number
227 of rare, but undetectable, variants in the inoculum by infecting with doses 20-fold higher than the
228 LD₅₀ of 3D^{G64S} (Table S3). Both viruses spread to the CNS and replicated to high titers after
229 intravenous inoculation, although WT titers in the brain and spinal cord were marginally higher
230 at 5 days post infection (Figure 4C, $p=0.0012$ for brain and $p=0.0221$ for spinal cord, Mann
231 Whitney U test). Here too, WT mice generally developed severe morbidity more rapidly than
232 those infected with 3D^{G64S}. We characterized the mutations present in the CNS populations of
233 12 spinal cords of intravenously infected mice (Fig. 4D, 7 WT and 5 3D^{G64S}). Most mutations

234 were rare, none were shared among mice, and there was an excess of synonymous or
235 noncoding variants relative to nonsynonymous ones. These data are consistent with random
236 sampling of the infecting population as opposed to positive selection.

237
238 We also examined the impact of the r-selected mutations on virulence. The $2C^{V127L}$ mutation,
239 which conferred a fitness of 1.11 in the $3D^{G64S}$ background and does not appear to affect fidelity
240 (Fig. S3), restored virulence to nearly WT levels ($p=0.0012$, log rank test, compare $3D^{G64S}$ to
241 $3D^{G64S};2C^{V127L}$ in Fig. 4E). In contrast, the triple mutant, $3D^{G64S;I92T;K276R}$, which replicates with a
242 wild type mutation rate and a marginally increased fitness of 0.7637, was only slightly more
243 virulent than the high fidelity variant $3D^{G64S}$ ($p=0.0411$, log rank test, compare $3D^{G64S}$ to
244 $3D^{G64S;I92T;K276R}$ in Fig. 4F). Therefore, restoration of replicative speed restored virulence in
245 $3D^{G64S}$, but compensation of the fidelity phenotype did not.

246

247 **Discussion**

248 We used a well-studied antimutator variant of poliovirus to identify the selective forces that
249 optimize a pathogen's mutation rate. Using three different assays, we identified a significant
250 fitness cost to higher fidelity and directly link this cost to viral replication kinetics. Our
251 quantitative model of the speed-fidelity trade-off suggests that selection for replicative speed
252 has pushed viral mutation rates to a level that imposes a significant fitness cost at baseline due
253 to lethal or highly deleterious mutations. Consistent with the trade-off model, direct selection for
254 increased replicative speed led to indirect selection of polymerases with higher mutation rates.
255 The genetic interactions are quite strong as the two compensatory mutations exhibited
256 reciprocal sign epistasis. The speed-fidelity trade-off in the poliovirus RdRp appears to be a
257 generalizable phenomenon, as compensatory mutations that increased the replicative speed of
258 the $3D^{K359H}$ antimutator also increased its mutation rate (Table S4). Given the structural
259 similarity among viral RdRp, the polymerases of other RNA viruses are likely to be subject to the

260 same speed-fidelity trade-off, and we predict that the molecular mechanisms governing
261 polymerase kinetics and mutation rate will be similar.

262
263 Trade-offs are essentially constraints that force one parameter to change with another. In this
264 case, viral mutation rate changes with replicative speed [53]. Similar trade-offs are central to the
265 kinetic proofreading hypothesis, which posits a close relationship between the error rates of
266 biosynthetic processes and the kinetics of their component reactions [54]. Interestingly, studies
267 of DNA replication and protein translation suggest that these systems optimize speed over
268 accuracy, so long as the error rates are within a tolerable range [55,56]. We find a similar
269 phenomenon in viral RdRp, where the WT generates an extraordinary amount of mutational
270 load, largely because of the benefit in replicative speed.

271
272 Failure to consider evolutionary trade-offs can lead to teleological errors, in which the
273 consequences of a process (e.g. increased genetic diversity) are misinterpreted as a cause (e.g.
274 direct selection for a higher mutation rate [19,23,26]). Similarly, we find that the widely accepted
275 link between within host genetic diversity and virulence is confounded by the fact that faster
276 replicating viruses are both more virulent and have higher mutation rates. The high mutation
277 rates of RNA viruses and the highly deleterious fitness effects of mutations ensure that most
278 genetic diversity is extremely rare and unlikely to be consistently maintained in the face of
279 intrahost and interhost bottlenecks [52]. We do not dispute that virus populations will harbor
280 minority variants, that a subset of these mutations may be adaptive or beneficial to the virus,
281 and that some may be virulence determinants. However, the observation of genetic diversity is
282 not in and of itself evidence that selection has optimized mutation rates for the future benefit of
283 novel mutations. Indeed, our data show little adaptive benefit to a marginally increased mutation
284 rate and identify no plausible mechanism whereby the observed increase in rare genetic
285 diversity can influence pathogenesis. We suspect that RNA viruses are subject to other trade-

286 offs of evolutionary significance, perhaps between polymerase speed and recombination rate or
287 recombination rate and polymerase fidelity. Here too, it will be important to define the selective
288 forces at play, thereby separating the causes from the consequences.

289

290 **Methods**

291

292 *Cells and viruses*

293 A low passage stock of HeLa cells (<2 weeks in culture), previously obtained directly from
294 ATCC (CCL-2), was kindly provided by Mary O’Riordan (University of Michigan). Except where
295 noted, these cells were used for all experiments in this study and maintained in minimal
296 essential media (MEM, Invitrogen 11090), supplemented with 10% fetal bovine serum (Gibco or
297 Hyclone), 1x Penicillin-Streptomycin (Invitrogen 15140-148), 1x sodium pyruvate (Invitrogen
298 11360), 1x MEM alpha non-essential amino acids (Invitrogen 11140), 1x glutamine (Invitrogen
299 25030). A second stock of HeLa of unknown passage history was obtained from Michael
300 Imperiale (University of Michigan). These cells were only used for plaque assays to titer stocks
301 and were maintained in Dulbecco’s modified Eagle’s media (DMEM, Invitrogen 11965)
302 supplemented with 10% fetal bovine serum and 1x Penicillin-Streptomycin. PVR-3T3 cells are
303 described below and were maintained in DMEM supplemented with 10% fetal bovine serum, 1x
304 Penicillin-Streptomycin and 1x glutamine. In all cases, cell lines were maintained for no more
305 than 30 passages at a time. Wild type poliovirus and all mutants were generated from plasmid
306 pEW-M, a Mahoney clone originally obtained from Eckard Wimmer (SUNY-Stonybrook) [57].

307

308 *Generation of PVR-3T3 cells*

309 The University of Michigan Institutional Animal Care and Use Committee approved the protocols
310 for the mouse studies described here and below. C57/BL6 PVR-Tg21 (PVR) mice [44,45] were
311 obtained from S. Koike (Tokyo, Japan) via Julie Pfeiffer (UT Southwestern) and maintained in

312 specific pathogen free conditions. Primary mouse embryonic fibroblasts (MEF) were derived
313 from PVR mice. Day 13.5 embryos were harvested and washed in phosphate-buffered saline
314 (PBS). The heads and viscera were removed, and the body was minced with a sterile razor
315 blade, trypsinized, and homogenized by pipetting with a 10ml serological pipette. Cells were
316 plated in DMEM supplemented with 10% fetal bovine serum, 1x Penicillin-Streptomycin and 1x
317 glutamine. An immortalized cell was derived from PVR MEFs following the 3T3 protocol [58].
318 Briefly, freshly thawed MEFs were plated in 30 T25 flasks at a density of 3.8×10^5 cells per flask
319 in complete DMEM. Every third day, cells in each flask were trypsinized, counted, and
320 transferred to fresh flasks at a density of 3.8×10^5 cells per flask. As the cellular population
321 began to increase (passages 13-15), cells were expanded into larger vessels and ultimately
322 frozen down at passage 17.

323

324 *Site directed mutagenesis*

325 All mutations were introduced into either pEW-M or subclones using overlap extension PCR [59].
326 The presence of the desired mutation and the absence of additional mutations were verified by
327 Sanger sequencing of the amplified insert, and in some cases the entire genome.

328

329 *In vitro transcription, transfection, and viral stocks*

330 Viral RNA was generated by in vitro transcription of the corresponding plasmid clone using T7
331 RNA polymerase, and virus was recovered following RNA transfection of HeLa. For
332 transfections, 2.6×10^5 HeLa were plated per well in a 12 well plate the day prior. One
333 microgram of RNA was mixed with 4 μ l TransIT mRNA transfection reagent (Mirus 2225) and
334 100 μ l OptiMEM (Invitrogen 31985), incubated according to the manufacturer's protocol, and
335 applied to cells. Passage 0 virus was harvested at 100% CPE (within 24-48 hours). Passage 1
336 stocks were generated by passaging 100 μ l of passage 0 virus on fresh cells and were titered by
337 either plaque assay or TCID₅₀. Passage 2 and 3 stocks were generated by passaging at an MOI

338 0.01. For all stocks, cells were subjected to three freeze-thaw cycles and the supernatants
339 clarified by centrifugation a 1400 x g for 4 minutes. These supernatants were stored at minus
340 80°C in aliquots to limit the number of subsequent freeze-thaw cycles.

341

342 *Competition assay for viral fitness*

343 Competition assays were performed essentially as described in [17,42]. For the experiment in
344 Fig. 1A, HeLa cells were plated in 12 well plates, at a density of 2.6×10^5 per well the day prior
345 to infection. Cells were infected at a total MOI of 0.1 with an equal TCID₅₀ of WT and 3D^{G64S}.
346 Three replicate wells were infected with each pair of viruses in 250µl for one hour with
347 occasional rocking. After one hour, the inoculum was removed and 1ml fresh media applied.
348 Passage 1 virus was harvested after an additional 7 hours (8 hours since infection). The titer of
349 the passage 1 virus was used to calculate the dilution factor necessary to maintain an MOI of
350 0.1 for the subsequent 5 passages. RNA was harvested from each passage using Trizol
351 (Ambion 15596026). Random hexamers were used to prime cDNA synthesis with 1/10 of the
352 RNA. Each cDNA was analyzed by real time PCR using three different primer and/or probe sets
353 with duplicate PCR reactions for each sample/primer set. The first set, COM2F 5'
354 CATGGCAGCCCCGGAACAGG 3' and COM2R 5' TGTGATGGATCCGGGGGTAGCG 3', was
355 used to quantify total viral genomic RNA in a SYBR green reaction (Power SYBR Green PCR
356 Master Mix, Thermo 4368708). Two custom TaqMan probes (Applied Biosystems) were used to
357 quantify the number of WT and 3D^{G64S} genomes. Duplicate wells were averaged, and relative
358 amounts of WT and 3D^{G64S} RNA were determined by normalizing the cycle thresholds for each
359 these probes to those of the COM primer set ($\Delta Ct = Ct_{\text{virus}} - Ct_{\text{COM}}$). The normalized values for
360 virus passages 1–6 were then compared to passage 0 to obtain a ratio relative to P0 ($\Delta \Delta Ct =$
361 $\Delta Ct_{\text{PX}} - \Delta Ct_{\text{P0}}$). This relative Ct value was converted to reflect the fold change in the ratio ($\Delta \text{ratio} =$
362 $2^{-\Delta \Delta Ct}$). The change in ratio of the mutant relative to the change in ratio of the WT as a function
363 of passage is the fitness ($[\Delta \log \text{ratio}_{\text{Mut}} - \Delta \log \text{ratio}_{\text{WT}}] / \text{time}$). Competition assays in ribavirin (Fig.

364 1F) were performed in the exact same manner except that serum free media were used in both
365 drug and mock passages.

366

367 For all other competition assays (Fig. 3), we compared the experimental virus (e.g. WT P4,
368 3D^{G64S} P8 etc.) to a tagged WT reference (Tag8). We plated 2.6×10^5 cells per well (either HeLa
369 or PVR 3T3) in 12 well plates. Infections were performed at an MOI of 0.05 in 250 μ l complete
370 media for 1 hour. After an hour, the media were aspirated and fresh 1ml growth media applied.
371 All passages were for 24 hours. The dilution factor between passages required to maintain this
372 MOI was 400 for HeLa competitions and 350 for PVR-3T3 competitions. All RNA harvests for
373 these competitions were performed in 96 well plates using Purelink Pro 96 Viral RNA/DNA kits
374 (Invitrogen 12280) and cDNA synthesis performed as above. In addition to the COM primer set
375 (see above) we used primer pairs Tag8 seq.tag 5' TTCAGCGTCAGGTTGTTGA 3' + Rev. WT
376 seq.tag 5' CAGTGTTTGGGAGAGCGTCT 3' and WT seq.tag 5' AGCGTGCGCTTGTTGCGA 3'
377 + Rev. WT seq.tag 5' CAGTGTTTGGGAGAGCGTCT 3' to quantify the Tag8 reference and test
378 samples respectively. Note also that in these competitions, the regressions were fit through
379 passages 1–4 and excluded P0 as slight deviations from a 1:1 ratio of the two viruses in the
380 inoculum can skew the slope when fit through this data point.

381

382 *Plaque size assay*

383 Plaque assays were performed on subconfluent monolayers (7.5×10^6 on day of infection) in
384 10cm dishes. The amount of virus applied to each plate was determined empirically to ensure
385 well spaced plaques (~30 per 10cm dish). Plates were stained with crystal violet at 72 hours
386 post infection. Each plate was scanned individually at 300 dpi using a flat-bed scanner. Sixteen
387 bit image files were analyzed using ImageJ. Brightness, contrast, and circularity thresholds for
388 plaque identification were set using uninfected plates.

389

390 *Single replication cycle growth curve*

391 The day prior to infection, 4×10^5 HeLa cells were plated in 12 well plates with 45 wells per virus
392 (9 time points and 5 replicates per time point). Cells were infected at an MOI of 1 in 150 μ l
393 volume and incubated on ice for 1 hour with occasional rocking. At one hour, the inocula were
394 aspirated, each well was washed twice with ice cold PBS, and 1ml of fresh, pre-warmed growth
395 media were applied to all wells. One set of 5 wells was immediately frozen as the t=0h time
396 point. All other plates were returned to the incubator, and a set of 5 wells was removed and
397 frozen at t=1.5, 2, 2.5, 3, 3.5, 4, 5, and 7 hours. All samples were titered by TCID₅₀. The growth
398 curve on PVR-3T3 cells was performed using a similar protocol, except that 5×10^5 cells were
399 plated the day prior and the time points were t=1, 2, 3, 4, 5, 6, 7, and 8 hours.

400

401 *Measurement of viral mutation rates*

402 Mutation rates were measured by Luria-Delbruck fluctuation test, which in this case quantifies
403 the rate at which the poliovirus 2C protein acquires the necessary point mutations to permit viral
404 growth in 1mM guanidine hydrochloride [60-62]. Each fluctuation test was performed with 29
405 replicate cultures in 48 well plates. Sixty five thousand HeLa cells per well were plated the day
406 prior to infection. In all cases, the media were changed to serum free media 3 hours prior to
407 infection. For infections in ribavirin, this serum free media also included drug at the specified
408 concentrations. Each well was infected in 200 μ l volume with 1000-4000 pfu per well depending
409 on the virus and experimental condition. Five independent aliquots were also saved for
410 subsequent titering (see N_i below). For infections in ribavirin, the infection media also included
411 drug at the specified concentrations. Infected cells were incubated for 7 hours and then frozen.
412 The lysed cells and media were harvested following three complete freeze-thaw cycles and
413 transferred to a microcentrifuge tube. The empty wells were rinsed with 300 μ l of complete
414 growth media and combined with the initial 200 μ l lysate. This 500 μ l lysate was clarified by
415 centrifugation at 1400 x g for 4 minutes. Twenty-four wells were titered by plaque assay with

416 1mM guanidine hydrochloride in the overlay (see P_0 below). Five wells were titered by standard
417 plaque assay without guanidine hydrochloride (see N_f below). The mutation rate, μ_0 , was
418 estimated from these data using the P_0 null-class model: $\mu_0 = -\ln P_0 / (N_f - N_i)$, where P_0 was the
419 fraction of the cultures that yielded no guanidine resistant plaques, N_f was the average number
420 of pfu in the absence of guanidine and N_i was the average number of pfu in the inoculum. As
421 described in [63], μ_0 can be converted to the mutation rate in nucleotide units by correcting for
422 the mutation target (number of mutations leading to the scored phenotype, T) and the number of
423 possible mutations at each target site (constant, 3) using the equation $\mu = 3\mu_0/T$. The number of
424 distinct mutations that could yield the guanidine resistant phenotype was determined empirically
425 by isolating and sequencing the entire 2C open reading frame for 15 guanidine resistant
426 plaques derived from WT virus and 15 guanidine resistant plaques derived from WT virus
427 treated with 200 μ M ribavirin. In each case we found 6 mutations that mediated resistance,
428 although there were 7 total among 30 plaques (Table S1).

429

430 *Mutagen sensitivity assay*

431 HeLa cells were plated the day prior to infection at a density of 2.6×10^5 cells per well in a 12
432 well dish. On the day of infection, monolayers were pretreated with 0–600 μ M ribavirin in serum-
433 free media for 3 hours, then infected with virus at an MOI of 0.1 (50,000 pfu) for 60 min. The
434 cells were washed once in phosphate buffered saline and incubated in ribavirin for an additional
435 24 hours. Viral supernatants were harvested by freeze-thaw as above and titered by tissue
436 culture infectious dose.

437

438 *R-selection through serial passage*

439 For each passage, HeLa cells were plated the day prior to infection in 6 well plates at a density
440 of 7.25×10^5 cells per well, yielding 1.2×10^6 cells on the day of infection. Infections were
441 initiated with passage 3 stocks of either WT or 3D^{G64S}, and each passage was performed at an

442 MOI of 0.5 (6×10^5 TCID₅₀ units) in 1ml of media for one hour with occasional rocking. After one
443 hour, the inoculum was aspirated, the cells were washed twice with PBS, and 2ml of fresh
444 growth media applied. For the first 15 passages, WT and 3D^{G64S} viruses were harvested at 4
445 and 4.5 hours, respectively. For passages 16-50, WT and 3D^{G64S} viruses were harvested at 3.5
446 and 4 hours, respectively. Control populations were infected in the same manner except that
447 viruses were harvested at 24 hours post infection. There were (5) r-selected WT lineages, (5) r-
448 selected 3D^{G64S} lineages, (5) control WT lineages, and (5) control 3D^{G64S} lineages. Viruses were
449 titered at every 5th passage to maintain an MOI of approximately 0.5.

450

451 *Selection and identification of second-site suppressors of RdRp variant 3D^{K359H}*

452 The 3D^{K359R} RdRp has slower polymerization kinetics and higher fidelity relative to WT [64]. The
453 3D^{K359H} RdRp has similar characteristics (see Table S4). HeLa cells were transfected by
454 electroporation with viral RNA transcript, added to HeLa cell monolayers and incubated at 37°C.
455 After two days the media were passaged onto a separate monolayer of HeLa cells. Upon
456 cytopathic effect, viruses were harvested by three repeated freeze-thaw cycles, cell debris was
457 removed by centrifugation, and viral supernatants were titrated. In this time frame, the titer
458 increased approximately 40-fold (from 5.1×10^5 pfu/mL to 2.1×10^7). Viral RNA was isolated
459 with QIAamp viral RNA purification kits (Qiagen), according to the manufacturer's instructions.
460 The 3Dpol cDNA was prepared from purified viral RNA by RT-PCR and sequenced. The I331F
461 and P356S substitutions were identified together in one experiment, and the P356S substitution
462 was identified in a second (see Table S4).

463

464 *In vitro assays of RdRp function*

465 All mutations were introduced into the pET26Ub-PV 3D [65] or pSUMO-PV-3D [66] bacterial
466 expression plasmids using either overlap extension PCR or QuickChange Site-Directed
467 Mutagenesis. The presence of the desired mutations and the absence of additional mutations

468 were verified by DNA sequencing. PV 3Dpol RdRps were expressed and purified as described
469 previously [65,66]. The sym-sub assays used to measure assembly/elongation kinetics of
470 purified RdRp on a defined template were performed as described in [6,30,67]. All assays had 1
471 μM primer/template and 2 μM enzyme.

472

473 *Adaptability of WT and 3D^{G64S}*

474 For HeLa cells, adaptability was measured using the 24 hour passage control lineages from the
475 r-selection experiment. The fitness values of WT and 3D^{G64S} populations were measured by
476 competition assay, as above, using samples from passages 0, 5, 10, 15, and 20. For PVR 3T3
477 cells, serial passages were performed as follows. Cells were seeded in 6 well plates at a density
478 of 7.6×10^5 cells per well the day prior to infection, yielding approximately 1×10^6 the day of
479 infection. Serial passage lineages were initiated with passage 1 stocks of either WT or 3D^{G64S},
480 and each passage was performed at an MOI of 0.5 in 1ml for one hour. After one hour, the
481 inoculum was aspirated, the cells were washed twice with PBS, and 2ml of fresh growth media
482 applied. Viruses were harvested at 24 hours and titered every 4th passage to ensure an MOI of
483 0.5. There were (5) replicate lineages of WT and 3D^{G64S}.

484

485 *Infection of transgenic mice*

486 This study was approved by the Institutional Animal Care and Use Committee at the University
487 of Michigan and is compliant with all relevant ethical regulations. Six to 9 week old mice were
488 used for all experiments. The age range and distribution of males and females in each group for
489 each experiment are reported in Table S2. On the day of each infection, a general health exam
490 was performed on all animals by University veterinary technical staff and animals were assigned
491 unique ear tag identifiers. For survival analyses, mice were infected intramuscularly with 50 μl to
492 each hindlimb for the total dose of 100 μl . Mice were observed twice daily for lethargy, hunched
493 posture, scruffy fur, paralysis, or decreased mobility and euthanized when they exhibited

494 bilateral hindlimb paralysis. Over 90% of all assessments were performed by members of the
495 University veterinary technical staff, who were blinded to the hypotheses and expected
496 outcomes of the studies. All surviving animals were euthanized after 12 days. These endpoints
497 were also used to calculate the PD50 using the Spearman-Kärber method (Table S3).

498

499 For tissue distribution analyses, mice were infected intravenously via tail vein with 100µl and
500 observed twice daily as above. Mice were euthanized for severe morbidity or on day 5, the
501 conclusion of the experiment. Whole organs were isolated from all mice and homogenized in
502 PBS using a Bead Beater. The homogenates were clarified by centrifugation at 15,800 x g for 4
503 minutes in a microfuge and the supernatant extracted with chloroform. Half of this supernatant
504 was titered by TCID₅₀. RNA was extracted from the remainder using Trizol.

505

506 *Next generation sequencing*

507 We amplified poliovirus genomes as four overlapping cDNA by RT-PCR. RNA was harvested
508 from either cell free supernatants or tissues as above and was reverse transcribed using the
509 SuperScript III First Strand Synthesis System for RT-PCR (Invitrogen 18080) and a mixture of
510 random hexamers and oligo dT primer. The four genomic fragments were amplified using primer
511 pairs: WFP37 FORWARD BASE 1 5' TTAAACAGCTCTGGGGTTGTACC 3' + WFP41
512 REVERSE BASE 2434 5' GCGCACGCTGAAGTCATTACACG 3'; WFP39 FORWARD BASE.
513 1911 5' TCGACACCATGATTCCCTTTGACT 3' + WFP42 REVERSE BASE 4348 5'
514 AATTCCTGGTGTTCTGACTA 3'; WFP13 FORWARD BASE 4087 5'
515 ATGCGATGTTCTGGAGATACCTTA 3' + WFP43 REVERSE BASE 5954 5'
516 CCGCTGCAAACCCGTGTGA 3'; WFP40 FORWARD BASE 5545 5'
517 TTTACCAACCCACGCTTCACCTG 3' + WFP33 REVERSE BASE 7441 5'
518 CTCCGAATTAAAGAAAAATTTACCCC 3'. The thermocycler protocol was: 98°C for 30 sec then
519 30 cycles of 98°C for 10 sec, 68°C for 20 sec, 72°C for 3 min, followed by a single cycle of 72°C

520 for 5 min, then 4°C hold. For each sample, amplification of all 4 fragments was confirmed by gel
521 electrophoresis and equal quantities of each PCR product were pooled. Seven hundred fifty
522 nanograms of each cDNA mixture were sheared to an average size of 300 to 400bp using a
523 Covaris S220 focused ultrasonicator. Sequencing libraries were prepared using the NEBNext
524 Ultra DNA library prep kit (NEB E7370L), Agencourt AMPure XP beads (Beckman Coulter
525 A63881), and NEBNext multiplex oligonucleotides for Illumina (NEB E7600S). The final
526 concentration of each barcoded library was determined by Quanti PicoGreen dsDNA
527 quantification (ThermoFisher Scientific), and equal nanomolar concentrations were pooled.
528 Residual primer dimers were removed by gel isolation of a 300-500bp band, which was purified
529 using a GeneJet Gel Extraction Kit (ThermoFisher Scientific). Purified library pools were
530 sequenced on an Illumina MiSeq with 2 x 250 nucleotide paired end reads. All raw sequence
531 data have been deposited at the NCBI short read archive (Bioproject PRJNA396051,
532 SRP113717).

533

534 *Variant detection*

535 Sequencing reads that passed standard Illumina quality control filters were binned by index and
536 aligned to the reference genome using bowtie [68]. Single nucleotide variants (SNV) were
537 identified and analyzed using DeepSNV [69], which relies on a clonal control to estimate the
538 local error rate within a given sequence context and to identify strand bias in base calling. The
539 clonal control was a library prepared in an identical fashion from the pEW-M plasmid and was
540 sequenced in the same flow cell to control for batch effects. True positive SNV were identified
541 from the raw output tables by applying the following filtering criteria in R: (i) Bonferonni
542 corrected p value <0.01, (ii) average MapQ score on variant reads >20, (iii) average phred score
543 on variant positions >35, (iv) average position of variant call on a read >62 and <188, (v) variant
544 frequency >0.001. We only considered SNV identified in a single RT-PCR reaction and
545 sequencing library for samples with copy number $\geq 10^5$ genomes/ μ l supernatant or in two

546 separate RT-PCR reactions and sequencing libraries for samples with copy number 10^3 - 10^5
547 genomes per μ l (for example in tissue studies). Our strategy for variant calling as well as our
548 benchmarked sensitivity and specificity are described in [46] and all code can be found at
549 https://github.com/lauringlab/variant_pipeline.

550

551 *Statistical Analysis*

552 No explicit power analyses were used in designing the experiments. In most cases we used 5
553 biological replicates. In a few cases, we used fewer (3) or more (7) where the variance was
554 either sufficiently low or high. The number of replicates, the statistical tests used, and the
555 relevant p values are reported in each Figure legend or the main text (Fig. 2C and 2D only). All
556 replicates within the dynamic range of each assay are reported (i.e. no replicate experiments
557 were excluded). Data on the relative adaptability of WT and 3D^{G64S} populations were analyzed
558 with a 3-level linear mixed effects model estimating a random slope and intercept of time nested
559 within each fitness measurement replicate (measID), nested within each lineage replicate
560 (replID). Virus was included as a fixed effect. Models were fit with the R package lme4, all code
561 for this model can be found at https://github.com/lauringlab/speed_fidelity.

562

563 **References**

- 564 1. Duffy S, Shackelton LA, Holmes EC. Rates of evolutionary change in viruses: patterns
565 and determinants. *Nat Rev Genet.* 2008;9: 267–276. doi:10.1038/nrg2323
- 566 2. Sanjuán R. From molecular genetics to phylodynamics: evolutionary relevance of
567 mutation rates across viruses. *PLoS Pathog.* 2012;8: e1002685.
568 doi:10.1371/journal.ppat.1002685
- 569 3. Orr HA. The rate of adaptation in asexuals. *Genetics.* Genetics Society of America;
570 2000;155: 961–968.
- 571 4. Sanjuán R, Nebot MR, Chirico N, Mansky LM, Belshaw R. Viral mutation rates. *J Virol.*
572 2010;84: 9733–9748. doi:10.1128/JVI.00694-10
- 573 5. Pfeiffer JK, Kirkegaard K. A single mutation in poliovirus RNA-dependent RNA
574 polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity.

- 575 Proc Natl Acad Sci USA. 2003;100: 7289–7294. doi:10.1073/pnas.1232294100
- 576 6. Arnold JJ, Vignuzzi M, Stone JK, Andino R, Cameron CE. Remote site control of an
577 active site fidelity checkpoint in a viral RNA-dependent RNA polymerase. *J Biol Chem.*
578 2005;280: 25706–25716. doi:10.1074/jbc.M503444200
- 579 7. Vignuzzi M, Stone JK, Arnold JJ, Cameron CE, Andino R. Quasispecies diversity
580 determines pathogenesis through cooperative interactions in a viral population. *Nature.*
581 2006;439: 344–348. doi:10.1038/nature04388
- 582 8. Sierra M, Airaksinen A, González-López C, Agudo R, Arias A, Domingo E. Foot-and-
583 mouth disease virus mutant with decreased sensitivity to ribavirin: implications for error
584 catastrophe. *J Virol. American Society for Microbiology;* 2007;81: 2012–2024.
585 doi:10.1128/JVI.01606-06
- 586 9. Gnädig NF, Beaucourt S, Campagnola G, Bordería AV, Sanz-Ramos M, Gong P, et al.
587 Coxsackievirus B3 mutator strains are attenuated in vivo. *Proceedings of the National*
588 *Academy of Sciences.* 2012;109: E2294–303. doi:10.1073/pnas.1204022109
- 589 10. Coffey LL, Beeharry Y, Bordería AV, Blanc H, Vignuzzi M. Arbovirus high fidelity variant
590 loses fitness in mosquitoes and mice. *Proceedings of the National Academy of Sciences.*
591 2011;108: 16038–16043. doi:10.1073/pnas.1111650108
- 592 11. Miller JH. Spontaneous mutators in bacteria: insights into pathways of mutagenesis and
593 repair. *Annu Rev Microbiol.* 1996;50: 625–643. doi:10.1146/annurev.micro.50.1.625
- 594 12. Schaaper RM. Antimutator mutants in bacteriophage T4 and *Escherichia coli*. *Genetics.*
595 1998;148: 1579–1585.
- 596 13. Drake JW, Allen EF, Forsberg SA, Preparata RM, Greening EO. Genetic control of
597 mutation rates in bacteriophage T4. *Nature.* 1969;221: 1128–1132.
- 598 14. Sanjuán R, Moya A, Elena SF. The distribution of fitness effects caused by single-
599 nucleotide substitutions in an RNA virus. *Proc Natl Acad Sci USA.* 2004;101: 8396–8401.
600 doi:10.1073/pnas.0400146101
- 601 15. Sanjuán R. Mutational fitness effects in RNA and single-stranded DNA viruses: common
602 patterns revealed by site-directed mutagenesis studies. *Philos Trans R Soc Lond, B, Biol*
603 *Sci.* 2010;365: 1975–1982. doi:10.1098/rstb.2010.0063
- 604 16. Acevedo A, Brodsky L, Andino R. Mutational and fitness landscapes of an RNA virus
605 revealed through population sequencing. *Nature.* 2014;505: 686–690.
606 doi:10.1038/nature12861
- 607 17. Visher E, Whitefield SE, McCrone JT, Fitzsimmons W, Lauring AS. The Mutational
608 Robustness of Influenza A Virus. Ferguson NM, editor. *PLoS Pathog.* 2016;12:
609 e1005856–25. doi:10.1371/journal.ppat.1005856
- 610 18. Sturtevant AH. Essays on evolution. I. On the effects of selection on mutation rate. *Q Rev*
611 *Biol.* 1937. doi:10.2307/2808438

- 612 19. Sniegowski PD, Gerrish PJ, Johnson T, Shaver A. The evolution of mutation rates:
613 separating causes from consequences. *Bioessays*. John Wiley & Sons, Inc; 2000;22:
614 1057–1066. doi:10.1002/1521-1878(200012)22:12<1057::AID-BIES3>3.0.CO;2-W
- 615 20. Kimura M. On the evolutionary adjustment of spontaneous mutation rates*. *Genetics*
616 *Research*. Cambridge University Press; 1967;9: 23–34.
617 doi:10.1017/S0016672300010284
- 618 21. Leigh EG Jr. Natural selection and mutability. *American Naturalist*. 1970.
619 doi:10.2307/2459161
- 620 22. Drake JW. Rates of spontaneous mutation among RNA viruses. *Proc Natl Acad Sci USA*.
621 1993;90: 4171–4175.
- 622 23. Belshaw R, Gardner A, Rambaut A, Pybus OG. Pacing a small cage: mutation and RNA
623 viruses. *Trends Ecol Evol (Amst)*. 2008;23: 188–193. doi:10.1016/j.tree.2007.11.010
- 624 24. Andino R, Domingo E. Viral quasispecies. *Virology*. 2015;479-480: 46–51.
625 doi:10.1016/j.virol.2015.03.022
- 626 25. Bordería AV, Rozen-Gagnon K, Vignuzzi M. Fidelity Variants and RNA Quasispecies.
627 Berlin, Heidelberg: Springer Berlin Heidelberg; 2015. pp. 1–20.
628 doi:10.1007/82_2015_483
- 629 26. Elena SF, Sanjuán R. Adaptive value of high mutation rates of RNA viruses: separating
630 causes from consequences. *J Virol*. 2005;79: 11555–11558.
631 doi:10.1128/JVI.79.18.11555-11558.2005
- 632 27. Smith EC, Sexton NR, Denison MR. Thinking Outside the Triangle: Replication Fidelity of
633 the Largest RNA Viruses. *Annual Review of Virology*. Annual Reviews; 2014;1: 111–132.
634 doi:10.1146/annurev-virology-031413-085507
- 635 28. Eckerle LD, Becker MM, Halpin RA, Li K, Venter E, Lu X, et al. Infidelity of SARS-CoV
636 Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing.
637 *PLoS Pathog*. 2010;6: e1000896. doi:10.1371/journal.ppat.1000896
- 638 29. Graham RL, Becker MM, Eckerle LD, Bolles M, Denison MR, Baric RS. A live, impaired-
639 fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of
640 lethal disease. *Nat Med*. 2012. doi:10.1038/nm.2972
- 641 30. Korboukh VK, Lee CA, Acevedo A, Vignuzzi M, Xiao Y, Arnold JJ, et al. RNA Virus
642 Population Diversity: An Optimum for Maximal Fitness and Virulence. *J Biol Chem*.
643 American Society for Biochemistry and Molecular Biology; 2014;: jbc.M114.592303.
644 doi:10.1074/jbc.M114.592303
- 645 31. Rozen-Gagnon K, Stapleford KA, Mongelli V, Blanc H, Failloux A-B, Saleh M-C, et al.
646 Alphavirus mutator variants present host-specific defects and attenuation in mammalian
647 and insect models. Kramer LD, editor. *PLoS Pathog*. 2014;10: e1003877.
648 doi:10.1371/journal.ppat.1003877
- 649 32. Furió V, Moya A, Sanjuán R. The cost of replication fidelity in an RNA virus. *Proc Natl*

- 650 Acad Sci USA. 2005;102: 10233–10237. doi:10.1073/pnas.0501062102
- 651 33. Furió V, Moya A, Sanjuán R. The cost of replication fidelity in human immunodeficiency
652 virus type 1. *Proc Biol Sci*. 2007;274: 225–230. doi:10.1098/rspb.2006.3732
- 653 34. Vignuzzi M, Wendt E, Andino R. Engineering attenuated virus vaccines by controlling
654 replication fidelity. *Nat Med*. 2008;14: 154–161. doi:10.1038/nm1726
- 655 35. Van Slyke GA, Arnold JJ, Lugo AJ, Griesemer SB, Moustafa IM, Kramer LD, et al.
656 Sequence-Specific Fidelity Alterations Associated with West Nile Virus Attenuation in
657 Mosquitoes. *PLoS Pathog*. Public Library of Science; 2015;11: e1005009.
658 doi:10.1371/journal.ppat.1005009
- 659 36. Pfeiffer JK, Kirkegaard K. Increased fidelity reduces poliovirus fitness and virulence under
660 selective pressure in mice. *PLoS Pathog*. 2005;1: e11. doi:10.1371/journal.ppat.0010011
- 661 37. Levi LI, Gnädig NF, Beaucourt S, McPherson MJ, Baron B, Arnold JJ, et al. Fidelity
662 variants of RNA dependent RNA polymerases uncover an indirect, mutagenic activity of
663 amiloride compounds. *PLoS Pathog*. 2010;6: e1001163.
664 doi:10.1371/journal.ppat.1001163
- 665 38. Cheung PPH, Watson SJ, Choy K-T, Fun Sia S, Wong DDY, Poon LLM, et al. Generation
666 and characterization of influenza A viruses with altered polymerase fidelity. *Nature*
667 *Communications*. 2014;5: 4794. doi:10.1038/ncomms5794
- 668 39. Campagnola G, McDonald S, Beaucourt S, Vignuzzi M, Peersen OB. Structure-Function
669 Relationships Underlying the Replication Fidelity of Viral RNA-Dependent RNA
670 Polymerases. Kirkegaard K, editor. *J Virol*. 2014;89: 275–286. doi:10.1128/JVI.01574-14
- 671 40. Burch CL, Chao L. Evolvability of an RNA virus is determined by its mutational
672 neighbourhood. *Nature*. 2000;406: 625–628. doi:10.1038/35020564
- 673 41. Codoñer FM, Darós J-A, Solé RV, Elena SF. The fittest versus the flattest: experimental
674 confirmation of the quasispecies effect with subviral pathogens. *PLoS Pathog*. 2006;2:
675 e136. doi:10.1371/journal.ppat.0020136
- 676 42. Lauring AS, Acevedo A, Cooper SB, Andino R. Codon usage determines the mutational
677 robustness, evolutionary capacity, and virulence of an RNA virus. *Cell Host and Microbe*.
678 2012;12: 623–632. doi:10.1016/j.chom.2012.10.008
- 679 43. Crotty S, Maag D, Arnold JJ, Zhong W, Lau JY, Hong Z, et al. The broad-spectrum
680 antiviral ribonucleoside ribavirin is an RNA virus mutagen. *Nat Med*. 2000;6: 1375–1379.
681 doi:10.1038/82191
- 682 44. Koike S, Taya C, Kurata T, Abe S, Ise I, Yonekawa H, et al. Transgenic mice susceptible
683 to poliovirus. *Proc Natl Acad Sci USA*. National Academy of Sciences; 1991;88: 951–955.
- 684 45. Ida-Hosonuma M, Iwasaki T, Yoshikawa T, Nagata N, Sato Y, Sata T, et al. The
685 alpha/beta interferon response controls tissue tropism and pathogenicity of poliovirus. *J*
686 *Virol*. 2005;79: 4460–4469. doi:10.1128/JVI.79.7.4460-4469.2005

- 687 46. McCrone JT, Lauring AS. Measurements of Intrahost Viral Diversity Are Extremely
688 Sensitive to Systematic Errors in Variant Calling. *J Virol.* 2016;90: 6884–6895.
689 doi:10.1128/JVI.00667-16
- 690 47. Baltimore D, Girard M, Darnell JE. Aspects of the synthesis of poliovirus RNA and the
691 formation of virus particles. *Virology.* 1966;29: 179–189.
- 692 48. Pfeiffer JK, Kirkegaard K. Bottleneck-mediated quasispecies restriction during spread of
693 an RNA virus from inoculation site to brain. *Proc Natl Acad Sci USA.* 2006;103: 5520–
694 5525. doi:10.1073/pnas.0600834103
- 695 49. Kuss SK, Etheredge CA, Pfeiffer JK. Multiple host barriers restrict poliovirus trafficking in
696 mice. *PLoS Pathog.* 2008;4: e1000082. doi:10.1371/journal.ppat.1000082
- 697 50. Lancaster KZ, Pfeiffer JK. Limited Trafficking of a Neurotropic Virus Through Inefficient
698 Retrograde Axonal Transport and the Type I Interferon Response. Gale M, editor. *PLoS*
699 *Pathog.* 2010;6: e1000791. doi:10.1371/journal.ppat.1000791.g006
- 700 51. Varble A, Albrecht RA, Backes S, Crumiller M, Bouvier NM, Sachs D, et al. Influenza A
701 virus transmission bottlenecks are defined by infection route and recipient host. *Cell Host*
702 *and Microbe.* 2014;16: 691–700. doi:10.1016/j.chom.2014.09.020
- 703 52. Zwart MP, Elena SF. Matters of Size: Genetic Bottlenecks in Virus Infection and Their
704 Potential Impact on Evolution. *Annual Review of Virology.* 2015;2: 161–179.
705 doi:10.1146/annurev-virology-100114-055135
- 706 53. Dulin D, Vilfan ID, Berghuis BA, Hage S, Bamford DH, Poranen MM, et al. Elongation-
707 Competent Pauses Govern the Fidelity of a Viral RNA-Dependent RNA Polymerase.
708 *CellReports.* 2015. doi:10.1016/j.celrep.2015.01.031
- 709 54. Hopfield JJ. Kinetic proofreading: a new mechanism for reducing errors in biosynthetic
710 processes requiring high specificity. *Proc Natl Acad Sci USA.* 1974;71: 4135–4139.
- 711 55. Murugan A, Huse DA, Leibler S. Speed, dissipation, and error in kinetic proofreading.
712 *Proceedings of the National Academy of Sciences.* National Acad Sciences; 2012;109:
713 12034–12039. doi:10.1073/pnas.1119911109
- 714 56. Banerjee K, Kolomeisky AB, Igoshin OA. Elucidating interplay of speed and accuracy in
715 biological error correction. *Proceedings of the National Academy of Sciences.* National
716 *Acad Sciences;* 2017;17: 201614838. doi:10.1073/pnas.1614838114
- 717 57. Mueller S, Papamichail D, Coleman JR, Skiena S, Wimmer E. Reduction of the rate of
718 poliovirus protein synthesis through large-scale codon deoptimization causes attenuation
719 of viral virulence by lowering specific infectivity. *J Virol.* 2006;80: 9687–9696.
720 doi:10.1128/JVI.00738-06
- 721 58. TODARO GJ, GREEN H. Quantitative studies of the growth of mouse embryo cells in
722 culture and their development into established lines. *J Cell Biol.* 1963;17: 299–313.
- 723 59. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR. Site-directed mutagenesis by overlap
724 extension using the polymerase chain reaction. *Gene.* 1989;77: 51–59.

- 725 60. Pincus SE, Wimmer E. Production of guanidine-resistant and -dependent poliovirus
726 mutants from cloned cDNA: mutations in polypeptide 2C are directly responsible for
727 altered guanidine sensitivity. *J Virol.* 1986;60: 793–796.
- 728 61. Pincus SE, Diamond DC, Emini EA, Wimmer E. Guanidine-selected mutants of
729 poliovirus: mapping of point mutations to polypeptide 2C. *J Virol.* 1986;57: 638–646.
- 730 62. Baltera RF, Tershak DR. Guanidine-resistant mutants of poliovirus have distinct
731 mutations in peptide 2C. *J Virol.* 1989;63: 4441–4444.
- 732 63. Combe M, Sanjuán R. Variation in RNA Virus Mutation Rates across Host Cells. Lauring
733 A, editor. *PLoS Pathog.* 2014;10: e1003855. doi:10.1371/journal.ppat.1003855.s001
- 734 64. Weeks SA, Lee CA, Zhao Y, Smidansky ED, August A, Arnold JJ, et al. A Polymerase
735 mechanism-based strategy for viral attenuation and vaccine development. *J Biol Chem.*
736 *American Society for Biochemistry and Molecular Biology;* 2012;287: 31618–31622.
737 doi:10.1074/jbc.C112.401471
- 738 65. Gohara DW, Ha CS, Kumar S, Ghosh B, Arnold JJ, Wisniewski TJ, et al. Production of
739 “authentic” poliovirus RNA-dependent RNA polymerase (3D(pol)) by ubiquitin-protease-
740 mediated cleavage in *Escherichia coli*. *Protein Expr Purif.* 1999;17: 128–138.
741 doi:10.1006/prev.1999.1100
- 742 66. Arnold JJ, Bernal A, Uche U, Sterner DE, Butt TR, Cameron CE, et al. Small ubiquitin-like
743 modifying protein isopeptidase assay based on poliovirus RNA polymerase activity. *Anal*
744 *Biochem.* 2006;350: 214–221. doi:10.1016/j.ab.2005.11.001
- 745 67. Castro C, Smidansky E, Maksimchuk KR, Arnold JJ, Korneeva VS, Götte M, et al. Two
746 proton transfers in the transition state for nucleotidyl transfer catalyzed by RNA- and
747 DNA-dependent RNA and DNA polymerases. *Proc Natl Acad Sci USA. National Acad*
748 *Sciences;* 2007;104: 4267–4272. doi:10.1073/pnas.0608952104
- 749 68. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment
750 of short DNA sequences to the human genome. *Genome Biol.* 2009;10: R25.
751 doi:10.1186/gb-2009-10-3-r25
- 752 69. Gerstung M, Beisel C, Rechsteiner M, Wild P, Schraml P, Moch H, et al. Reliable
753 detection of subclonal single-nucleotide variants in tumour cell populations. *Nature*
754 *Communications.* 2012;3: 811. doi:10.1038/ncomms1814

755

756 **Acknowledgements**

757 We thank Ashley Acevedo, Leonid Brodsky, and Raul Andino for providing the raw data on
758 poliovirus mutational fitness effects; Santiago Elena and Rafael Sanjuan for helpful suggestions;
759 Carla Pretto, Rajni Sharma, Jacob Perryman and Alexandre Martinez for technical assistance.

760 This work was supported by R01 AI118886 to ASL and R01 AI 45818 to CEC. RW was
761 supported by K08 AI119182 and JTM was supported by the Michigan Predoctoral Training
762 Program in Genetics (T32 GM007544).

763

764 **Figure Legends**

765 Figure 1: A speed-fidelity trade-off in the poliovirus RdRp. (A) Relative fitness of 3D^{G64S} as
766 measured by direct competition. The amount of each virus at each passage was compared to
767 the input and expressed as the difference in the log₁₀ ratio in RNA genomes for 3D^{G64S} (open
768 circles) relative to WT over time. The slope of the dotted lines are the relative fitness values,
769 0.78 ± 0.01 , n=3 replicates. (B) Cumulative distribution function of fitness values for single
770 nucleotide variants of poliovirus as determined in [16]. * indicates the relative fitness (0.78) and
771 percentile (64th) of 3D^{G64S}. (C) Plaque size of clones from WT (n=272, black) and 3D^{G64S} (n=220,
772 grey) virus populations. Box plots show median, 25% and 75% quartiles, and 1.5x interquartile
773 range. *** $p \leq 0.005$, t-test with Welch's correction. (D) Single cycle growth curve for WT (filled
774 circles, black line) and 3D^{G64S} (open circles, grey line) in HeLa. Data are mean \pm standard
775 deviation (n=5 replicates). *** $p < 0.005$, unpaired t-test comparing WT and 3D^{G64S} separately for
776 each time point. (E) Single cycle growth curve for WT (filled circles, black line) and 3D^{G64S} (open
777 circles, grey line) in 3T3 cell line derived from MEF of PVR transgenic mice. Data are mean \pm
778 standard deviation (n=5 replicates). ** $p < 0.01$ *** $p < 0.005$, unpaired t-test comparing WT and
779 3D^{G64S} separately for each time point. (F) Relative fitness of 3D^{G64S} (open circles) as measured
780 by competition assay (see panel A) in the presence of varying concentrations of ribavirin. Note
781 the baseline relative fitness of 3D^{G64S} (y-intercept) is lower than the fitness reported in panel A
782 as the assays were performed under different experimental conditions (see methods). (G)
783 Mutation rate in mutations per nucleotide per strand copied for WT (filled circles) and 3D^{G64S}
784 (open circles) in the presence of varying concentrations of ribavirin, as determined by Luria

785 Delbruck fluctuation test.

786

787 Figure 2. R-selection leads to increased mutation rates. (A) A point mutant of 3D^{G64S} (GGT^{gly} to
788 AGT^{ser}) was introduced into a poliovirus genome that is marked with a nearby point mutation
789 that ablates an *AccI* restriction site. Viruses were serially passaged every 4.5 hours (r-selected)
790 or every 24 hours (control) for 15 passages. Chromatograms show the codon for position 64
791 (either GGT^{gly} or AGT^{ser}). Gel image of *AccI* restriction digest of all passage 15 populations
792 showing that the reversion occurred in the parental backbone and was not due to contamination
793 with WT virus, which retains the *AccI* site. (B) WT and a “locked in” version of 3D^{G64S} (GGT^{gly} to
794 UCA^{ser}) were subjected to r-selection (3.5-4 hour and 4-4.5 hour, respectively) or control (24
795 hour) passages for 50 passages as described in the text. Heatmap shows all mutations
796 identified at >0.025 frequency in ≥2 out of the 20 total lineages, colored by log frequency.
797 Diagram at left shows regions of the poliovirus genome. (C) Fitness of indicated variants relative
798 to WT as determined by competition assay. Each symbol is a replicate competition assay and
799 exact p-values for the key comparisons are provided in the main text. (D) Mutation rate of
800 indicated variants in mutations per nucleotide per strand copied as determined by Luria
801 Delbruck fluctuation test. Each symbol is a replicate fluctuation test and exact p-values for the
802 key comparisons are provided in the main text. (E) In vitro kinetics of purified RdRp. Purified
803 RdRp (2μM), primer-template (1μM) and ATP were incubated, and samples were quenched at
804 the indicated time points (schematic). The kinetics of complex assembly and single-base
805 incorporation are expressed as μM extended template (y-axis) over time (x-axis).

806

807 Figure 3: Adaptability of WT and 3D^{G64S} over 20 passages in HeLa (A) or 12 passages in a 3T3
808 cell line derived from mice transgenic for the poliovirus receptor (B). Fitness values (≥ 3

809 replicate competition assays for each data point) were determined for populations from every 5th
810 passage (A) or every 4th passage (B) and the adaptability in the top panels expressed as the
811 slope of the regression for log fitness over time for each of 5 independent lineages of WT (filled
812 circles) and 3D^{G64S} (open circles, blue) for each cell line. The bottom panels show all the data
813 from the 5 lineages together with the regression of log fitness over time. Exact p-values for the
814 difference between the slopes for WT and 3D^{G64S} on HeLa (0.0129) and PVR-3T3 (0.0013) were
815 derived from a mixed linear effects model (see Methods).

816

817 Figure 4: In vivo phenotype of WT and 3D^{G64S} (A) Maximum likelihood optimization of a simple
818 binomial model (see Supporting Information Model 2) estimated an average inoculum to CNS
819 bottleneck size of 2.67 (lambda 2.44, 95% CI 1.39-3.82) based on experimental data for 4
820 barcoded poliovirus populations [48]. Shown are outputs of 10,000 simulations of the model
821 (number of mice with one, two, three, or four barcodes represented in the CNS). Each
822 simulation represents 27 mice and each mouse has a bottleneck size drawn from a zero-
823 truncated Poisson with an average lambda of 2.43 (blue) or 10 (magenta). Line is actual data
824 from [48], the shaded regions represent the area occupied by 95% of the simulations, and the
825 dark shaded regions representing the interquartile range of the simulations. (B) Survival curves
826 showing mice with paralysis free survival over time for groups (n=18 per virus) infected
827 intramuscularly with 10⁵ pfu (left), 10⁶ pfu (center), and 10⁷ pfu (right) of WT (black) or 3D^{G64S}
828 (dashed blue). * p<0.05, *** p<0.001 by Log rank test. (C) Viral titer in brain and spinal cord 5
829 days post intravenous inoculation with 10⁷ pfu of WT (filled circles) or 3D^{G64S} (open circles). *
830 p<0.05, **p<0.005 by Mann Whitney U test, n=7 mice in each group (out of 8 that were infected,
831 one mouse in each group had titers below the limit of detection, dotted line). One mouse in each
832 group had titers below the limit of detection (dotted lines). (D) Histogram of frequencies of
833 intrahost SNV identified in the spinal cords of 12 mice from panel D (7 infected with WT and 5

834 infected with 3D^{G64S}). Black, synonymous or noncoding; blue, nonsynonymous. (E) Survival
835 curves showing mice with paralysis free survival over time for groups (n=43 per virus combined
836 from two experiments) infected intramuscularly with 10⁶ pfu of 3D^{G64S} (dashed blue), or 3D^{G64S} ;
837 2C^{V127L} (orange). ** p<0.005, by Log rank test, actual p value 0.0012. (F) Survival curves
838 showing mice with paralysis free survival over time for groups (n=43 per virus combined from
839 two experiments) infected intramuscularly with 10⁶ pfu of 3D^{G64S} (dashed blue), or 3D^{G64S}; I92T ;
840 K276R (pink) *p<0.05 by Log rank test, actual p value 0.0411.

841

Figure 1




Figure 1: A speed-fidelity trade-off in the poliovirus RdRp. (A) Relative fitness of 3DG64S as measured by direct competition. The amount of each virus at each passage was compared to the input and expressed as the difference in the log₁₀ ratio in RNA genomes for 3DG64S (open circles) relative to WT over time. The slope of the dotted lines are the relative fitness values, 0.78 ± 0.01 , $n=3$ replicates. (B) Cumulative distribution function of fitness values for single nucleotide variants of poliovirus as determined in reference 16. * indicates the relative fitness (0.78) and percentile (64th) of 3DG64S. (C) Plaque size of clones from WT ($n=272$, black) and 3DG64S ($n=220$, grey) virus populations. Box plots show median, 25% and 75% quartiles, and 1.5x interquartile range. *** $p \leq 0.005$, t-test with Welch's correction. (D) Single cycle growth curve for WT (filled circles, black line) and 3DG64S (open circles, grey line) in HeLa. Data are mean \pm standard deviation ($n=5$ replicates). *** $p < 0.005$, unpaired t-test comparing WT and 3DG64S separately for each time point. (E) Single cycle growth curve for WT (filled circles, black line) and 3DG64S (open circles, grey line) in 3T3 cell line derived from MEF of PVR transgenic mice. Data are mean \pm standard deviation ($n=5$ replicates). ** $p < 0.01$ *** $p < 0.005$, unpaired t-test comparing WT and 3DG64S separately for each time point. (F) Relative fitness of 3DG64S (open circles) as measured by competition assay (see panel A) in the presence of varying concentrations of ribavirin. Note the baseline relative fitness of 3DG64S (y-intercept) is lower than the fitness reported in panel A as the assays were performed under different experimental conditions (see methods). (G) Mutation rate in mutations per nucleotide per strand copied for WT (filled circles) and 3DG64S (open circles) in the presence of varying concentrations of ribavirin, as determined by Luria Delbruck fluctuation test.

Figure 2




Figure 2. R-selection leads to increased mutation rates. (A) A point mutant of 3D^{G64S} (GGTgly to AGTser) was introduced into a poliovirus genome that is marked with a nearby point mutation that ablates an *AccI* restriction site. Viruses were serially passaged every 4.5 hours (r-selected) or every 24 hours (control) for 15 passages. Chromatograms show the codon for position 64 (either GGTgly or AGTser). Gel image of *AccI* restriction digest of all passage 15 populations showing that the reversion occurred in the parental backbone and was not due to contamination with WT virus, which retains the *AccI* site. (B) WT and a “locked in” version of 3D^{G64S} (GGTgly to UCAser) were subjected to r-selection (3.5-4 hour and 4-4.5 hour, respectively) or control (24 hour) passages for 50 passages as described in the text. Heatmap shows all mutations identified at >0.025 frequency in ≥2 out of the 20 total lineages, colored by log frequency. Diagram at left shows regions of the poliovirus genome. (C) Fitness of indicated variants relative to WT as determined by competition assay. Each symbol is a replicate competition assay and exact p-values for the key comparisons are provided in the main text. (D) Mutation rate of indicated variants in mutations per nucleotide per strand copied as determined by Luria Delbruck fluctuation test. Each symbol is a replicate fluctuation test and exact p-values for the key comparisons are provided in the main text. (E) In vitro kinetics of purified RdRp. Purified RdRp (2μM), primer-template (1μM) and ATP were incubated, and samples were quenched at the indicated time points (schematic). The kinetics of complex assembly and single-base incorporation are expressed as μM extended template (y-axis) over time (x-axis).

Figure 3




Figure 3: Adaptability of WT and 3DG64S over 20 passages in HeLa (A) or 12 passages in a 3T3 cell line derived from mice transgenic for the poliovirus receptor (B). Fitness values (≥ 3 replicate competition assays for each data point) were determined for populations from every 5th passage (A) or every 4th passage (B) and the adaptability in the top panels expressed as the slope of the regression for log fitness over time for each of 5 independent lineages of WT (filled circles) and 3DG64S (open circles, blue) for each cell line. The bottom panels show all the data from the 5 lineages together with the regression of log fitness over time. Exact p-values for the difference between the slopes for WT and 3DG64S on HeLa (0.0129) and PVR-3T3 (0.0013) were derived from a mixed linear effects model (see Methods).

Figure 4




Figure 4: In vivo phenotype of WT and 3DG64S (A) Maximum likelihood optimization of a simple binomial model (see Extended Data Model 2) estimated an average inoculum to CNS bottleneck size of 2.67 (λ 2.44, 95% CI 1.39-3.82) based on experimental data for 4 barcoded poliovirus populations 48. Shown are outputs of 10,000 simulations of the model (number of mice with one, two, three, or four barcodes represented in the CNS). Each simulation represents 27 mice and each mouse has a bottleneck size drawn from a zero-truncated Poisson with an average λ of 2.43 (blue) or 10 (magenta). Line is actual data from reference 48, the shaded regions represent the area occupied by 95% of the simulations, and the dark shaded regions representing the interquartile range of the simulations. (B) Survival curves showing mice with paralysis free survival over time for groups ($n=18$ per virus) infected intramuscularly with 10^5 pfu (left), 10^6 pfu (center), and 10^7 pfu (right) of WT (black) or 3DG64S (dashed blue). * $p < 0.05$, *** $p < 0.001$ by Log rank test. (C) Viral titer in brain and spinal cord 5 days post intravenous inoculation with 10^7 pfu of WT (filled circles) or 3DG64S (open circles). * $p < 0.05$, ** $p < 0.005$ by Mann Whitney U test, $n=7$ mice in each group (out of 8 that were infected, one mouse in each group had titers below the limit of detection, dotted line). One mouse in each group had titers below the limit of detection (dotted lines). (D) Histogram of frequencies of intrahost SNV identified in the spinal cords of 12 mice from panel D (7 infected with WT and 5 infected with 3DG64S). Black, synonymous or noncoding; blue, nonsynonymous. (E) Survival curves showing mice with paralysis free survival over time for groups ($n=43$ per virus combined from two experiments, see Table S2) infected intramuscularly with 10^6 pfu of 3DG64S (dashed blue), or 3DG64S ; 2CV127L (orange). ** $p < 0.005$, by Log rank test, actual p value 0.0012. (F) Survival curves showing mice with paralysis free survival over time for groups ($n=43$ per virus combined from two experiments, see Table S2) infected intramuscularly with 10^6 pfu of 3DG64S (dashed blue), or 3DG64S ; I92T ; K276R (pink) * $p < 0.05$ by Log rank test, actual p value 0.0411.

842 **Supporting Information Model 1 – Speed fidelity trade off**

843 The premise of the speed-fidelity tradeoff is that the outcome of competition between two viral
844 strains will be determined by two opposing forces – the speed with which the genome can be
845 replicated and the error rate of replication. The faster genome replication happens, the more
846 errors that occur and the greater the mutational load. In this scenario an optimal competitive
847 fitness will be achieved exactly where the increase in fitness is counterbalanced by decrease in
848 fitness from excess mutational load. Here we present a simple mathematical model to
849 demonstrate this tradeoff, and fit the model to the experimental data.

850

851 We start with the classical estimation by Haldane (1937) of the equilibrium mean population
852 fitness, w , as a function of the genomic deleterious mutation rate (U_d) in units of deleterious
853 mutations per genome per generation.


854

855 $w = e^{-U_d}$

856

857 The relationship is shown graphically, here.

858



859

860

861 Now we consider competition between two strains that differ in both their speed, c , and their

862 fidelity (as manifest by a deleterious mutation rate, U). If you have two strains, a and b , then the

863 relative fitness of a to b will be:

864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880


$$w_{a,b} = (c_a e^{-U_a}) / (c_b e^{-U_b})$$

Where c_a and c_b are the genome replication rates and U_a and U_b are the deleterious genomic mutation rates per genome per generation for strains a and b, respectively.

To understand the effect of a mutagen on the relative fitness of one strain to another, we add a mutation rate multiplier (mu external, σ), which multiplicatively modifies the baseline mutation rate. We constrain σ to take values greater than one.

$$w_{a,b} = (c_a e^{-U_a \cdot \sigma}) / (c_b e^{-U_b \cdot \sigma})$$


As shown below, as the mutation rate multiplier goes up, the fitness of a high fidelity variant increases relative to wild type (WT). The plot on the left shows both strains (WT and a high fidelity variant together). The equilibrium, where the two strains have equal fitness, is at a sigma value where the two lines cross (as indicated by the arrow, right)



881
882
883
884
885
886
887
888

With this simple model, we can use the empirical estimates of mutation rates and relative fitness values over a range of ribavirin concentrations (which increase the mutation rate multiplier, σ) to estimate the deleterious mutation rate and the amount of mutation load experienced by WT poliovirus and the 3D^{G64S} high fidelity variant. The data are presented in Figures 1E and 1F and available in the annotated Jupyter notebook available at https://github.com/lauringlab/speed_fidelity.

889



890

891

892 The G64S mutation has two effects (see also Fig. 1F). The mutation results in an increase in
893 fidelity, represented as a downward shift in the line. The mutation also results in relative
894 resistance to ribavirin, which manifests as a decreased slope. Both of these need to be included
895 to estimate the mutational load experienced by WT and the 3D^{G64S} mutant replicating in the
896 presence of increasing mutagen. Linear regression fit to both the WT and 3D^{G64S} mutation rate
897 produce a good fit (r^2 of .73 and .76 respectively) that is highly statistically significant ($p < 0.001$
898 for both). The fit of the linear regression was used to estimate the mutation rate for WT and
899 3D^{G64S} in the absence of ribavirin (1.34×10^{-5} s/n/r and 3.43×10^{-6} s/n/r respectively) and at the
900 point of equilibrium.

901

902 We solved for the two unknown variables: (i) n , the number of deleterious sites in the genome,
903 and (ii) c , the fitness cost of the G64S mutation in the absence of mutational load, which is
904 relative to the wild type (arbitrarily set to 1). Because there are two unknown variables, we need
905 two equations to solve for them. We use the measured relative fitness in the absence of ribavirin
906 and the ribavirin concentration where the relative fitness is expected to be 1 (150μM, see Fig.
907 1E). We used the mutation rates estimated for each strain and ribavirin concentration
908 (μ strain,conc). At 0μM ribavirin, the fitness of 3D^{G64S} relative to WT was measured as 0.67,
909 which gives us our first equation:

910

911

$$c * e^{-\mu_{G64S,0} * n} / e^{-\mu_{wt,0} * n} = 0.67$$

912

913 Next, we looked at the competitive fitness data and used the point at which the two strains have

914 equal fitness (approximately 150 μ M of ribavirin, see Fig. 1E):

915

916

$$c * e^{-\mu_{G64S,150} * n} / e^{-\mu_{wt,150} * n} = 1.0$$

917

918 Now, with two equations, we solved for the two unknown values (n and c). Assuming they have

919 equal fitness at 150 μ M, the fitness cost of 3D^{G64S} absent the cost from mutational load is 0.60.

920 The effective number of sites with deleterious mutations is 10959 (48% of all possible mutations,

921 given 3 possibilities at every site). The fitness cost due to mutational load that is experienced by

922 WT in absence of ribavirin is 0.137. The fitness cost due to mutational load experienced by


923 3D^{G64S} in absence of ribavirin is 0.037. These relationships are shown graphically below, where

924 the dashed line indicates the fitness in the absence of mutational load, the shaded area

925 indicates the effect of mutational load on fitness and the solid lines indicate the overall effect on

926 fitness.

927



928

929

930 **Supporting Information Model 2 – Within host bottleneck**

931 We developed the following model to measure the effective bottleneck that restricts poliovirus
932 populations between the site of inoculation and the central nervous system. We applied a
933 simple probabilistic model to data described in [48]. In this study, 27 mice were infected with 2 x
934 10⁷ PFU of poliovirus (2-5 fold higher than the LD₅₀ in this particular mouse model). The inocula
935 consisted of 4 subpopulations at equal concentrations, each tagged with a neutral sequence bar
936 code. In separate experiments, the authors showed that all 4 bar codes were present at the site
937 of infection and that all four bar codes were capable of replicating simultaneously in the brain.
938 Rarely were all 4 bar codes present in the brain following infection, suggesting that the
939 populations were subject to within host bottlenecks. Similar results were observed for IV and IP
940 routes of infection. In fact, IM appeared to be the least stringent mode of infection. To estimate
941 the bottleneck between the site of infection and the brain, we modeled the infection process as
942 a random sampling event. This assumption was justified as: (i) there is no evidence that a
943 "jackpot" mutation is needed to enter the central nervous system. (ii) the bar codes were
944 selectively neutral. (iii) all bar codes were equally likely to be present in the brain.

945

946 The probability of a sample size of n containing K unique types given there are N total unique
947 types available (all present at equal frequency) derives from discrete probability theory and is
948 given by

949

$$P(K|N, n) = \binom{N}{k} \left(\frac{k}{N}\right)^n \left[1 - \sum_{i=1}^{k-1} \binom{k}{i} \left(\frac{k-i}{k}\right)^n (-1)^{i+1}\right]$$

950

951 (see for example, Ross SM. 2010. *A First Course in Probability*. Prentice Hall, pages 121-122).

952 In terms of the above experimental design, we are interested in the probability a subset of size n
953 containing 1,2,3, or 4 barcodes (K) given 4 possible barcodes (N).

954

955 Maximum likelihood optimization revealed that a bottleneck of 4 PFU best matched the data.

956 However, this model was constrained, in part, by the fact that no smaller bottleneck could

957 account for the presence of 4 barcodes in the CNS even though this rarely occurred. Indeed

958 simulations revealed this model predicted a higher average number of barcodes than

959 experimentally observed. In particular the model underestimated the probability of only 1

960 barcode infecting the CNS.

961

962 To account for experimental variability in bottleneck sizes between mice we allowed the

963 bottleneck to vary according to a zero-truncated Poisson distribution. We truncated the Poisson

964 distribution because at the high doses used in the original experiment and replicated in this

965 current work poliovirus entered the CNS in all infected mice. That is, there were no mice with

966 zero barcodes.

967

968 When we allow n , the bottleneck size, and in our model, to follow a zero-truncated Poisson

969 distribution parameterized with λ . The likelihood of observing k barcodes given λ is


$$L(\lambda) = P(K|\lambda) = \sum^n P(K|N, n)P(n|\lambda)$$

970 Where $P(k|N, n)$ is our expression above and $P(n|\lambda) = \frac{\lambda^n}{(e^n - 1)n!}$ or the probability of n in a zero-

971 truncated Poisson with a parameter λ . We approximated the infinite sum above with a partial


972 sum of the first 100 terms as we expected a small bottleneck, and the probability of an n of 50

973 with $\lambda = 100$ is on the order of 10^{-10} and negligible. We then searched for the λ that maximized
974 the sum of the log of this likelihood, which was calculated for each mouse. We found that a λ of
975 2.44 with a 95% confidence interval of (1.39 - 3.82) best fit the data. The mean of a zero-
976 truncated Poisson is given by $\frac{\lambda e^\lambda}{e^\lambda - 1}$. Therefore the mean bottleneck size is 2.67.




977
978 To test the fit we performed 10,000 simulations. Each simulation included 27 mice and each
979 mouse had a bottleneck size drawn from a zero-truncated Poisson with a λ of 2.44. For
980 illustration we also simulated the data with an average bottleneck of 10. The output of the
981 simulations is shown below and in Fig. 4A. The shaded regions represent the area occupied by
982 95% of the simulations with the dark regions representing the interquartile range of the
983 simulations.

984




985

986 We also checked the fit by asking how the output of the simulations matched the actual
987 experimental data (e.g. how often did we see 9 mice with 1 bar code, 10 with 2, 7 with 3, and 1
988 with 4).



989

990 In contrast, we did not replicate the data once in 10,000 simulations with a bottleneck of 10.



991

992 While we modeled the infectious process from inoculation to invasion of the CNS as a single
993 sampling procedure, this process is made up of several bottlenecks imposed on the virus as it
994 passes through different body compartments [49]. We, therefore, interpret our mean bottleneck
995 of 2.67 as an aggregate, within-host bottleneck.

996

997 Population bottlenecks have been show to be dose dependent. However, it is likely that the
998 inoculating dose modeled here, and used in the presented work, saturates this dose
999 dependency. For example, Pfeiffer et al. only observed a slight increase in the average number
1000 of barcodes present in the CNS when mice were inoculated with 100x more PFU. In fact, the
1001 bottleneck appears to only be overcome when very young (two week old) mice were inoculated.

1002

1003 **Table S1.** Mutations conferring resistance to 1mM guanidine. Shown are results from 15
 1004 plaques from populations treated with no drug (WT) or 200µM ribavirin (R).
 1005

Plaque	Mutations (position, nucleotide change, amino acid change)	Plaque 200µM R	Mutations (position, nucleotide change, amino acid change)
WT2	4614 U->A, F->Y	R1	4676 G->U, A->S
WT6	4614 U->A, F->Y	R8	4676 G->U, A->S
WT12	4614 U->A, F->Y	R10	4676 G->U, A->S
WT14	4676 G->U, A->S	R12	4676 G->U, A->S
WT1	4682 A->U, M->L	R13	4676 G->U, A->S
WT3	4682 A->U, M->L	R7	4363 C->U, VAL(SYN) ; 4682 A->C, M->L
WT4	4682 A->U, M->L	R3	4702 G->A, M->I
WT5	4682 A->U, M->L	R2	4802 A->C, I->L
WT9	4682 A->U, M->L	R4	4802 A->C, I->L
WT10	4682 A->U, M->L	R5	4802 A->C, I->L ; 4810 C->U,PRO(SYN)
WT11	4682 A->U, M->L	R6	4797 G->A,SER(SYN) ; 4820 G->A, A->U
WT7	4702 G->A, M->I	R9	4820 G->U, A->S
WT13	4820 G->U, A->S	R11	4459 A->G, I->M ; 4820 G->U, A->S
WT8	4442 A->G,U->A ; 4823 C->A,H->N	R14	4820 G->U, A->S
WT15	NONE in 2C	R15	4823 C->A, H->N

1006

1007 **Table S2.** Number, age, and sex of mice used in all experiments.

1008

Expt	Route	Dose	Age Range	WT	3D ^{G64S}	3D ^{G64S} -2C ^{V127L}	3D ^{G64S ;I92T; K276R}
IV1043	IM	10 ⁶	6w3d-8w6d	18 (8♂ , 10♀)	18 (9♂ , 9♀)	18 (9♂ , 9♀)	
IV1044	IV	10 ⁷	6w6d-8w4d	15 (6♂ , 9♀)	16 (6♂ , 10♀)	16 (6♂ , 10♀)	
IV1045	IM	10 ⁵	6w1d-8w3d	12 (6♂ , 6♀)	12 (6♂ , 6♀)	12 (6♂ , 6♀)	
IV1048	IM	10 ⁴	6w4d-7w1d	12 (6♂ , 6♀)	12 (6♂ , 6♀)		
IV1049	IM	10 ⁷	7w-7w2d	18 (11♂ , 7♀)	18 (11♂ , 7♀)		
IV1052	IM	10 ⁶	6w-7w6d	16 (7♂ , 9♀)	18 (8♂ , 10♀)		
IV1053	IV	10 ⁷	6w3d-8w1d	10 (4♂ , 6♀)	10 (5♂ , 5♀)		
IV1054	IM	Var ^a	6w3d-8w1d	24 (12♂ , 12♀)	24 (13♂ , 11♀)		
IV1055	IM	10 ⁶	7w-7w4d		25 (11♂ , 14♀)	25 (11♂ , 14♀)	
IV1056	IM	10 ⁶	6w-6w3d		25 (12♂ , 13♀)		25 (13♂ , 12♀)
IV1057	IM	10 ⁶	6w3d-7w2d		18 (9♂ , 9♀)		18 (9♂ , 9♀)

1009

1010

1011

^a Varied dose for LD50 estimation. See Table S3

1012 **Table S3.** Raw data for calculation of LD50 (PD50, as paralysis triggered euthanasia per
1013 protocol). Calculation and output were obtained using tsk package in R with no trimming. Similar
1014 values were obtained using the logit method.

1015

	10 ² pfu	10 ³ pfu	10 ⁴ pfu	10 ⁵ pfu	10 ⁶ pfu	10 ⁷ pfu	PD50	95% CI	
WT	0/6	0/6	3/6	5/6	6/6	6/6	1.47E+05	4.7E+04	4.6E+05
3D ^{G64S}	ND	0/6	1/6	3/6	6/6	6/6	6.81E+05	2.2E+05	2.1E+06

Age range 6w3d-8w1d; 25♂, 23♀

All animals dosed intramuscularly

PD50 by Spearman-Kärber method

1016

1017

1018 **Table S4.** Kinetic parameters for nucleotide incorporation and misincorporation for purified
1019 RdRp. The k_{pol} for the correct nucleotide measures the speed of polymerization in vitro. The
1020 $k_{pol,corr}/k_{pol,incorr}$ is an in vitro surrogate for fidelity, as it measures the relative rates of incorporation
1021 for the correct and incorrect nucleotides. A higher ratio indicates higher fidelity.

1022

RdRp	Correct Nucleotide		Incorrect Nucleotide	
	k_{pol} (s^{-1})	$K_{d,app}$ (μM)	k_{pol} (s^{-1}) [$\times 10^{-3}$] ^a	$k_{pol,corr} / k_{pol,incorr}$
WT	37 ± 3	180 ± 40	4.2 ± 0.6	8,800
K359H	4.0 ± 0.2	250 ± 20	0.10 ± 0.02	40,000
I331F K359H	8.5 ± 0.1	170 ± 10	0.74 ± 0.13	11,000
P356S K359H	9.8 ± 0.3	110 ± 10	0.78 ± 0.09	13,000
I331F P356S K359H	17 ± 1	120 ± 10	4.9 ± 0.8	3,500

1023


1024 ^a Determined at saturating concentrations of nucleotide substrate.

1025

1026

1027

Figure S1



B

GMP misincorporation		
Enzyme	k_{pol} (s^{-1})	$K_{d,app}$ (μ M)
WT	$1.5 \pm 0.1 \times 10^{-2}$	250 ± 10
K276R	$5.0 \pm 0.1 \times 10^{-3}$	250 ± 80
G64S-K276R	$2.0 \pm 0.1 \times 10^{-3}$	300 ± 50
G64S	$4.0 \pm 0.1 \times 10^{-3}$	300 ± 40

Figure S1. In vitro assay of polymerase mediated single nucleotide incorporation. (A) Schematic of GTP misincorporation assay (G opposite the U). Primer-template (sym-subU) and polymerase are assembled in the absence of nucleotide. GTP and a 25-fold excess of unlabeled trap RNA are then added after an incubation period (Δt). Excess of RNA trap ensures that if the polymerase dissociates from primer-template it is taken up by the trap and cannot re-assemble. (B) k_{pol} and K_d for GMP misincorporation. Concentrations of GTP were used over time-points to calculate k_{pol} and K_d . Each GTP time-course was plotted to single exponential, then combined plot to hyperbola. Note that all polymerase variants have the I92T mutation.

Figure S2




Figure S3




Figure S3. Mutagen sensitivity of 2C-V127L variants. HeLa were infected at an MOI of 0.1 with the indicated viruses in presence of various concentrations of ribavirin. After 24 hours, titers of mock and ribavirin-treated populations were determined by TCID₅₀ and those of ribavirin-treated populations were normalized to mock-treated controls (mean of 5 measurements per virus). Shown are the changes in titer (y-axis, mean, 5 replicates) for each virus at each drug concentration (x-axis). A greater reduction in titer (more negative number) indicates higher mutagen sensitivity and suggests a higher baseline mutation rate.